🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — July 15, 2026

The S&P 500 Healthcare sector shows a clear divergence between top-line growth and bottom-line pressure. Johnson & Johnson (JNJ) delivered solid 6.6% YoY revenue growth and raised full-year guidance, but GAAP earnings were flat due to headwinds from STELARA biosimilar erosion and currency. Elevance Health (ELV) reported mixed Q2 results: operating revenue grew modestly (0.8% YoY) and adjusted EPS beat expectations, but GAAP EPS fell 13.1% and the Health Benefits segment operating gain plunged 42.6% YoY, signaling rising medical costs. Both companies raised adjusted EPS guidance, but the underlying quality of earnings diverges—JNJ's growth is broad-based while ELV's beat relied on a one-time below-the-line benefit of ~$0.80/share. A key portfolio-level pattern is margin compression in managed care versus stability in diversified healthcare, with ELV's operating expense ratio rising 100 bps YoY. Insider trading data was not reported in these filings, limiting conviction signals. The most critical development is the STELARA biosimilar impact on JNJ's pharma growth, which investors should monitor closely as it represents a structural headwind.

1 high priority 2 medium 3 total filings
· daily

US Earnings Financial Results SEC Filings — July 15, 2026

The 22 filings reveal a market bifurcated between established operators facing margin pressure and early-stage companies showing signs of life. Conagra's $3B impairment and Nike's flat revenue highlight consumer weakness, while SPACs like Plutonian and Illumination successfully raised capital. Revenue growth is concentrated in micro-cap turnarounds (NextTrip +945%, Awareness Group +552%), but cash burn remains severe across the cohort. Insider activity is notably absent, and capital allocation favors debt reduction over buybacks. Key themes include SPAC IPO momentum, consumer spending shifts to value, and a 'growth at any cost' dynamic in pre-revenue companies. The most actionable signals are the extreme revenue growth at NextTrip and Awareness Group, and the deep value opportunity in Arts Way Manufacturing's operational improvement.

22 high priority 22 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 15, 2026

The eight DEF 14A filings for the 2026 proxy season reveal a mix of governance practices across market caps. Key themes include virtual annual meetings (5 of 8 companies), shareholder proposals addressing ESG issues (Nike), and equity plan amendments (PEDEVCO). Small-cap issuers (SemiLEDs, Stran, PEDEVCO) show minimal compensation disclosure detail, while larger firms (Nike, Under Armour, La-Z-Boy) provide robust pay-for-performance rationale and stock ownership guidelines. Insider trading data was not available in these summaries, limiting conviction signals. The most notable shareholder engagement is at Nike, where two proposals target charitable and environmental disclosures. Overall, the filings indicate a governance landscape where institutional investors may push for greater transparency, particularly on compensation metrics and ESG risks.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 15, 2026

The IPO pipeline digest for July 15, 2026, reveals a bifurcated market: two clinical-stage biotech IPOs (Vogenx, Braveheart Bio) seek to capitalize on promising drug candidates, while two blank-check and restructuring filings (Churchill Capital XIII, Sono Group) reflect ongoing SPAC and cross-border M&A activity. However, the most critical theme is the severe financial distress among several filers—authID Inc. and Vogenx both report cash balances under $1.2M with going-concern doubts, and Rallybio’s cash burn rate has accelerated 26% YoY, necessitating a dilutive merger. Period-over-period trends show a mixed picture: Vogenx cut operating expenses 39% YoY but still faces a $1.4M working capital deficit, while Rallybio’s R&D spend jumped 26% YoY with no revenue. Forward-looking statements across filings highlight heavy reliance on IPO proceeds or M&A for survival, with no insider buying detected in any filing—a bearish signal for management conviction. The pipeline is dominated by high-risk, high-reward biotech plays and capital-intensive restructurings, with limited visibility on near-term profitability.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — July 15, 2026

All three filings in this digest center on Nasdaq non-compliance and imminent trading suspensions, creating a concentrated regulatory storm for micro-cap issuers on July 15, 2026. The most critical development is **SPAR Group's** definitive delisting on July 23, 2026, after shareholders rejected a reverse stock split, making its path to appeal the only remaining lifeline—a high-probability suspension event. **SemiLEDs** offers a contrasting narrative: after receiving a stockholders' equity deficiency notice in January 2026, the company submitted a compliance plan, saw equity improve to $3.1 million, and now believes it has regained compliance, though Nasdaq continues to monitor. **Triller Group** faces the tightest deadline, with a Panel exception requiring it to achieve a $1.00 closing bid for 20 consecutive business days by July 30, 2026—a binary catalyst given its history of repeated non-compliance and prior trading halt. Period-over-period data reveals no revenue or margin trends across these filings, as the filings are purely regulatory and non-financial; the core pattern is that all three companies faced equity or bid-price deficiencies, with SPAR Group being the most severe due to shareholder rejection of the cure. The aggregated insider activity is absent, capital allocation data is nil, and forward-looking guidance is limited to regulatory deadlines, underscoring that this stream is purely about listing viability rather than operational performance.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 15, 2026

This digest covers 20 filings from July 15, 2026, focusing on US executive and director changes. The most significant event is the CEO succession at The Hanover Insurance Group, where a well-planned transition from John C. Roche to COO Richard W. Lavey is set for year-end 2026, signaling stability. A notable pattern is the appointment of highly experienced industry veterans to boards, including James H. Bradshaw at RLI Corp, Randy Larsen at Hartford, and John W. Dietrich at American Airlines, all bringing decades of sector-specific expertise. The mining sector shows a positive operational move with Hycroft Mining appointing a new COO with deep sulfide processing experience. A governance red flag appears at GameSquare Holdings, which had to correct previously invalid option grants to its CEO and CFO, indicating past control weaknesses. The CFO retirement at Celldex Therapeutics introduces key-person risk, though the long transition period mitigates immediate concern. Overall, the filings reflect routine board refreshment and succession planning, with no widespread negative trends, but the GameSquare correction and the CFO departure at Celldex warrant monitoring.

20 high priority 20 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 15, 2026

This brief covers a single filing from Lipella Pharmaceuticals Inc., which filed for Chapter 11 bankruptcy on March 30, 2026, and subsequently entered into an Asset Purchase Agreement with XRAIY to sell substantially all of its assets. The sale was approved by the Bankruptcy Court on June 4, 2026. The company explicitly warns that trading in its common stock during the Chapter 11 case is highly speculative and may bear little or no relation to actual recovery for stockholders. With no period-over-period comparisons, insider trading activity, forward-looking guidance, or capital allocation data available in the enriched filing, the actionable insights are limited to the bankruptcy proceedings and the asset sale. The key development is the court-approved sale, which effectively ends the company's operations and leaves equity holders with likely zero recovery. This is a classic end-stage bankruptcy event with no turnaround potential, making it a high-risk situation for any remaining shareholders.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 15, 2026

The July 15, 2026, batch of 20 SEC filings reveals a pronounced wave of board refreshment and leadership succession across the insurance and energy sectors, with 7 of 20 filings involving director appointments or CEO transitions. Notably, the insurance sector shows a pattern of recruiting former C-suite executives from large brokers (Gallagher, AssuredPartners) to strengthen board expertise, while the energy sector sees deep operational talent (Hycroft Mining, Infinity Natural Resources) being added to drive growth strategies. A key governance concern emerges from GameSquare Holdings, which had to correct previously invalid option grants to its CEO and CFO, signaling potential internal control weaknesses. The most material event is the CEO succession at Hanover Insurance, a $5B+ market cap insurer, which provides a clear 6-month transition timeline. While no period-over-period financial comparisons were available in these specific filings, the insider activity and forward-looking data (e.g., Celldex CFO retirement, Lamb Weston plan amendment) offer actionable intelligence for portfolio positioning. Overall, the digest points to a healthy but cautious corporate governance environment, with a focus on orderly transitions and independent board composition.

20 high priority 20 total filings
· daily

USA Insider Trading Pulse — July 15, 2026

The July 15, 2026, insider trading pulse reveals a market characterized by routine director compensation and option exercises, punctuated by a few high-conviction signals. The most significant event is a massive, pre-planned option exercise by an ASE Technology director worth ~$271M, which, while large in notional value, is a non-cash event and not a sale. A clear bearish signal emerges from Tower Semiconductor, where the CEO sold over $8M in stock across multiple transactions, indicating potential top-side concern. Conversely, a bullish insider purchase by the CEO of Vivos Inc., a micro-cap, signals strong management conviction at a distressed price. The data is dominated by routine, non-discretionary insider activity—tax withholdings, RSU conversions, and director awards—which provide limited directional insight. A notable cluster of director awards at GDS Holdings and CACI International suggests standard compensation cycles rather than opportunistic trading. The overall sentiment is neutral, with actionable signals concentrated in a few outlier events.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 15, 2026

The USA M&A & Takeover Activity stream for July 15, 2026, reveals a bifurcated SPAC market: two struggling shells (Ribbon Acquisition Corp., PHP Ventures) are burning cash on extensions, while a new entrant (Samos Energy) and a sponsor-backed vehicle (Yorkville Acquisition Corp.) signal renewed appetite for energy-focused and structured deals. The most material event is Glucotrack's reverse merger with Lōkahi Therapeutics, a high-conviction transaction where Lōkahi will control ~90% of the combined entity, supported by a private placement. Constellation Acquisition Corp I is advancing its HiTech Minerals merger with a scheduled investor event, but lacks financial updates. Nuvalent's post-acquisition filing indicates a completed deal but offers no financial terms, limiting actionable insight. Period-over-period data is sparse across filings, but insider activity (sponsor note conversion) and capital allocation (trust extensions, IPO pricing) provide key signals. The overall theme is a 'survival of the fittest' SPAC environment, with energy and biotech/medtech emerging as preferred sectors.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 15, 2026

Overnight SEC filings reveal a stark bifurcation between companies executing well and those facing existential threats. The most critical theme is a wave of Nasdaq delistings, with five companies (Actelis Networks, American Rebel Holdings, Blue Hat Interactive, Captivision, Sleep Number, and X3 Holdings) all set to be removed from the exchange on July 23, 2026, representing a significant liquidity and reputational blow for shareholders. On the positive side, ASML delivered a standout quarter with Q2 2026 net sales of €9.3 billion and raised its full-year 2026 outlook to between €43 billion and €45 billion, signaling robust demand in the semiconductor capital equipment space. Insider activity was mixed but notable: the CEO of BeOne Medicines sold over $22 million in stock through a 10b5-1 plan, while the CEO of Grab Holdings also sold $1.56 million, creating negative sentiment. Conversely, the CEO of Navios Maritime Partners made small open-market purchases totaling ~$252K, a modestly bullish signal. Capital allocation trends were highlighted by AEON Biopharma's $13.75 million public offering to fund its biosimilar pipeline, and SK hynix's massive $26.5 billion ADR offering, the largest capital raise in the batch. A significant governance event is the activist filing at Tax-Free Fixed Income Fund for Puerto Rico Residents, where a group holding 13.2% of shares is pushing a shareholder proposal. Overall, the data suggests a market rewarding strong operational performance (ASML) while punishing companies with weak fundamentals or compliance issues, with the delisting cluster being the most actionable risk signal.

40 high priority 10 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 14, 2026

This digest covers 8 FDA approvals from July 8-14, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion). The batch is heavily weighted toward established generic entrants, with zero NMEs, zero true biosimilars, and zero significant label expansions; 6 of 8 approvals are rated neutral. Two approvals are flagged as mildly bullish: label expansions for Indocyanine Green injection (PROVEPHARM SAS) and Sodium Bicarbonate (AMNEAL EU LTD), though commercial details are undisclosed. No oncology, neurology, or high-growth therapeutic area clustering is present. The dominant theme is generic competition in mature small-molecule markets, with entrants from Indian and specialty generic houses (Ajanta Pharma, Laurus Labs, Glenmark, Macleods) and hospital supply players (Baxter). The highest-conviction signal is the mild bullish read from the two label expansions, but materiality is low given undisclosed peak sales and exclusivity terms. Key watch items include the lack of NME or novel biologic approvals, signaling a dry period for high-conviction biotech catalysts.

8 total filings
· daily

Big Pharma Approvals — July 14, 2026

This July 14, 2026 digest covers 3 approvals, all classified as 'Other' (non-NME, non-biosimilar, non-standard label expansion), generating 3 bullish signals with no bearish or neutral flags. The dominant theme is oncology, with two label expansions for Merck Sharp & Dohme's pembrolizumab (KEYTRUDA and KEYTRUDA QLEX) and one NME approval for Sanofi-Aventis' isatuximab-irfc (SARCLISA ESCENA) with Orphan Drug designation. The highest-conviction signal is Sanofi's isatuximab-irfc approval, given its NME status and Orphan exclusivity, which strengthens Sanofi's multiple myeloma franchise. Key watch items include the commercial impact of pembrolizumab's expanded indications on Merck's revenue trajectory and the pricing dynamics for isatuximab-irfc in a competitive myeloma landscape.

3 total filings
· daily

Orphan Drug Approvals — July 14, 2026

During this period, the FDA issued two approvals, both classified as 'Other' (non-standard actions), with zero NMEs, biosimilars, or traditional label expansions. The dominant therapeutic area is oncology, with both approvals targeting cancer indications. The highest-conviction signal is the NME approval of ISATUXIMAB-IRFC (SARCLISA ESCENA) by SANOFI-AVENTIS U.S. LLC, granted Orphan Drug designation, which strengthens Sanofi's oncology pipeline and commercial position in multiple myeloma. The second approval is a label expansion for MERCK SHARP DOHME's PEMBROLIZUMAB (KEYTRUDA), reinforcing its market leadership. Key risks include the lack of detailed commercial data (peak sales, pricing, exclusivity) and the potential for accelerated approval-related post-marketing requirements for ISATUXIMAB-IRFC.

2 total filings
· daily

New Drug Approvals (Original) — July 14, 2026

This digest covers 9 FDA approvals from July 8-10, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 9 'Other' approvals (including one NME classified as 'FALLBACK' and several generic/biosimilar-like entries). The dominant therapeutic theme is absent, as approvals span diverse agents (diagnostic dye, electrolyte, oncology monoclonal antibody, diabetes combination, antiviral, antifibrotic, vasopressor, vitamin, and antibacterial). The highest-conviction signal is the NME approval of Sanofi's ISATUXIMAB-IRFC (SARCLISA ESCENA) with Orphan Drug designation, representing a potential new multiple myeloma therapy with premium pricing and 7-year exclusivity. Key risks include the lack of commercial data (peak sales, pricing) for all approvals, and the 'FALLBACK' classification suggests these may be non-standard or supplemental approvals, limiting immediate investment catalysts.

9 total filings
· daily

Federal Construction & Infrastructure Contracts — July 14, 2026

This digest covers a single, large civilian infrastructure contract totaling $224.7 million, awarded by the Department of Homeland Security (DHS) to Fisher Sand & Gravel Co. for border infrastructure construction in Youngtown, AZ. The contract is a firm-fixed-price delivery order with a three-year performance period, and $169.1 million has already been outlaid, indicating strong execution progress. As a private company, Fisher Sand & Gravel presents no direct public equity exposure, but the award underscores sustained investment in border security by DHS/CBP, a politically sensitive area subject to funding volatility. The key risk is potential policy shifts in border security funding, which could affect future awards and the contractor's revenue concentration. No defense-related contracts were recorded in this period, reinforcing a purely civilian infrastructure theme.

1 total filings
· daily

DHS Homeland Security Contracts — July 14, 2026

This digest covers a single $224.7 million civilian contract from the Department of Homeland Security (DHS), specifically U.S. Customs and Border Protection (CBP), awarded to Fisher Sand & Gravel Co. for border infrastructure construction in Youngtown, AZ. The contract is a firm-fixed-price delivery order with a three-year performance period, and $169.1 million has already been outlaid, indicating strong execution progress. The highest-conviction signal is the neutral, revenue-concentrated nature of the award for a private company, with no direct public equity exposure. Key risks include political sensitivity of border security funding and fixed-price cost overruns, while the primary watch item is policy shifts affecting future border infrastructure awards.

1 total filings
· daily

New Federal Contractors — July 14, 2026

This digest covers a single $224.7 million contract awarded to Fisher Sand & Gravel Co. by the Department of Homeland Security (DHS) for border infrastructure construction in Youngtown, AZ. The contract is entirely civilian (0% defense-related) and carries a neutral signal strength of 5/10, reflecting balanced execution progress and political risk. The highest-conviction signal is the $169.1 million already outlaid on the $217.1 million firm-fixed-price delivery order, indicating strong performance but also significant revenue concentration for this private company. Key risks include potential policy shifts in border security funding and cost overruns on a fixed-price contract. No public equity exposure exists, limiting direct investment implications.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 14, 2026

This digest covers a single, large civilian contract modification from July 14, 2026: a $224.7 million firm-fixed-price delivery order awarded to Fisher Sand & Gravel Co. by the Department of Homeland Security (Customs and Border Protection) for border infrastructure construction in Arizona. The contract is entirely civilian, with no defense exposure, and carries a neutral signal due to its fixed-price structure and political sensitivity. The highest-conviction signal is the strong execution progress ($169.1M already outlaid), but the key risk is the concentration of revenue for a private contractor and potential funding volatility tied to border policy shifts. There are no public equity signals from this single award, making it a low-materiality event for institutional investors.

1 total filings
· daily

Contract Deobligations Alert — July 14, 2026

The single contract in this digest, a $224.7 million deobligation alert for Fisher Sand & Gravel Co. from the Department of Homeland Security (DHS/CBP), represents a neutral signal with no direct public equity exposure. The underlying $217.1 million firm-fixed-price delivery order for border infrastructure in Youngtown, AZ, shows strong execution progress with $169.1 million already outlaid, but the deobligation suggests a potential reduction in scope or funding adjustment. As a civilian agency contract in a politically sensitive area, it carries medium execution risk and budget volatility, with no defense-related exposure. The highest-conviction signal is the concentration risk for Fisher Sand & Gravel, a private firm, and the broader theme of sustained but politically cyclical border infrastructure investment.

1 total filings